Wordt geladen...
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
BACKGROUND: Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II trial of cabazitaxel plus abiraterone to assess the antitumor activity and tolerability in patients with progressive mCRPC after do...
Bewaard in:
| Gepubliceerd in: | Ann Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Oxford University Press
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5378222/ https://ncbi.nlm.nih.gov/pubmed/28039155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw441 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|